Negative / Null Result ReportOpen accessMedicine· cited by 10

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Janine Kutzsche; Nicoleta Carmen Cosma; Gunther Kauselmann; Friederike Fenski; Christine Bieniek; Tuyen Bujnicki; Marlene Pils; Oliver Bannach · 2025 · Nature Communications

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Self-replicating amyloid beta (Aβ) oligomers are considered as one of the major drivers for disrupted synaptic function and plasticity, leading to impaired neuronal viability and progression of Alzheimer's disease (AD). Here, we investigated the safety, tolerability and pharmacokinetics of the anti-oligomeric peptide PRI-002, which was developed to disassemble toxic Aβ oligomers into non-toxic monomers. In a randomized, double-blind, single-center phase 1b trial, 20 patients aged between 50 and 80 years, with mild neurocognitive impairment (MCI) or mild dementia due to AD were recruited. Eligi

Abstract by Janine Kutzsche; Nicoleta Carmen Cosma; Gunther Kauselmann; Friederike Fenski; Christine Bieniek; Tuyen Bujnicki; Marlene Pils; Oliver Bannach, Nature Communications (2025) — licensed CC BY 4.0.

Read the full paper (open access)